Loading...
XSTO
KAN
Market cap23mUSD
Jun 24, Last price  
1.86SEK
1D
0.54%
1Q
55.00%
Jan 2017
-92.40%
IPO
-95.46%
Name

Kancera AB

Chart & Performance

D1W1MN
No data to show
P/E
—
P/S
16,100.43
EPS
—
Div Yield, %
—
Shrs. gr., 5y
35.11%
Rev. gr., 5y
-66.29%
Revenues
14k
-98.65%
07,069,0003,839,0001,813,000470,000282,000308,000113,000358,0003,216,00090,0001,704,000753,0001,035,00014,000
Net income
-45m
L-31.32%
-7,147,000-18,410,000-33,488,000-7,418,000-15,979,000-19,612,000-22,308,000-56,198,000-45,935,000-36,095,000-47,558,000-45,686,000-52,484,000-64,888,999-44,566,000
CFO
-59m
L+5.14%
-5,644,000-23,214,000-27,081,000-6,638,000-19,105,000-20,658,000-23,103,000-53,541,000-45,043,000-33,286,000-46,046,000-44,125,000-47,562,000-55,672,000-58,531,000
Earnings
Aug 21, 2025

Profile

Kancera AB (Publ) develops drugs for inflammatory diseases and cancer in Sweden and internationally. The company is developing small molecule drug candidates KAND567, which is in phase IIa clinical trial for inflammatory heart disease following infarction, as well as KAND145, which is in phase I study in healthy subjects to document desired dose levels against cancer; and Phase IIa study for the treatment of ovarian cancer. It also develops HDAC for the treatment of nerve inflammation and pain; and ROR1 inhibitors for the treatment of solid tumors and blood cancers. Kancera AB (Publ) was founded in 2010 and is based in Solna, Sweden.
URL
https://kancera.com/
IPO date
Feb 21, 2011
Employees
4
Domiciled in
SE
Incorporated in
SE

Valuation

Title
SEK in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
14
-98.65%
1,035
37.45%
753
-55.81%
Cost of revenue
46,175
66,077
53,047
Unusual Expense (Income)
NOPBT
(46,161)
(65,042)
(52,294)
NOPBT Margin
Operating Taxes
(432)
Tax Rate
NOPAT
(46,161)
(65,042)
(51,862)
Net income
(44,566)
-31.32%
(64,889)
23.64%
(52,484)
14.88%
Dividends
Dividend yield
Proceeds from repurchase of equity
59,201
6,215
36,759
BB yield
-47.09%
-1.73%
-28.99%
Debt
Debt current
(2,174)
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
(46,362)
(45,693)
(97,324)
Cash flow
Cash from operating activities
(58,531)
(55,672)
(47,562)
CAPEX
Cash from investing activities
Cash from financing activities
59,201
6,215
36,190
FCF
(46,161)
(64,795)
(51,502)
Balance
Cash
46,362
45,692
95,149
Long term investments
1,000
1,000
Excess cash
46,361
45,641
95,112
Stockholders' equity
(32,788)
(357,908)
(294,668)
Invested Capital
95,088
405,573
399,405
ROIC
ROCE
EV
Common stock shares outstanding
115,332
81,503
59,534
Price
1.09
-75.34%
4.42
107.51%
2.13
-65.25%
Market cap
125,712
-65.10%
360,245
184.09%
126,807
-69.10%
EV
79,350
314,552
29,483
EBITDA
(46,161)
(62,042)
(51,934)
EV/EBITDA
Interest
118
Interest/NOPBT